{"entity":{"id":"nct06234072","kind":"trial","name":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","aka":[],"tldr":"A phase 2 trial of gemcitabine in pancreatic cancer, run by Shenzhen University General Hospital, not yet recruiting.","summary":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients is a phase 2, randomised interventional study registered as NCT06234072 by Shenzhen University General Hospital, with a registry enrolment figure of 120 participants, started 2024-02 and due to reach its primary completion in 2027-01. Interventions recorded: Astragalus + Gemcitabine; Gemcitabine alone. Conditions listed: Pancreatic Cancer. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06234072","url":"https://clinicaltrials.gov/study/NCT06234072"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06234072","phase":"2","setting":"Comparison of Neoadjuvant Treatment for Pancreatic Cancer: Astragalus Combined With Gemcitabine Versus Gemcitabine Alone - A Single-Center, Randomized, Double-Blind Study","sponsor":"Shenzhen University General Hospital","participation":[{"nct":"NCT06234072","source":"https://clinicaltrials.gov/study/NCT06234072","fetchedAt":"2026-10-07T16:54:23.000Z","studySha256":"3de981e08a837ee8465a4edc9c148337ab4647bd41cd42e3e6bd66b20fb6ee4d","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2024-02-02","leadSponsor":"Shenzhen University General Hospital","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":120,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-02","startedType":"estimated","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06234072/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}